Social Media Wiki

How One Pharma Company Successfully Manages YouTube

Today’s post features commentary from Gary Monk, Product Manager (Marketing) at Janssen-Cilag. Gary is responsible for (among other things) administering the company’s LivingwithADHD YouTube Channel. So, along with my commentary, Gary will share his perspective based on his experience with Janssen-Cilag’s relatively popular video, “ADHD: A day in the life.” More on that in a moment, but first a little background.

For whatever reason, YouTube seems to get lumped into the giant “social media” bucket. I suppose there are some social aspects to it, but that’s a debate for a different day. It’s in that bucket and that means that it makes most pharma companies nervous. By nervous, I mean that many haven’t even taken the leap onto YouTube even though the vast majority have content that is probably YouTube worthy. Those that have started with YouTube, for the most part, treat it purely as a broadcast medium. That means that they turn off comments and the ability to like (or dislike) a video. And, yes, YouTube uses Like, just as Facebook does.

However, a number of pharma and healthcare companies have already started their own YouTube channels or posted videos. There are about 30 examples on the Pharma and Healthcare Social Media Wiki. As I mentioned, the majority do not allow any form of commenting on their videos even though they should (see: “Healthcare and Pharma Social Media: It’s All About E.V.E.“). The rationale I’ve been given for this by these companies is that they are afraid people will post adverse events. Of course, you can probably see me banging my head on my desk now because you all know that I’m not a big believer in the validity of this excuse. Having said that, I thought I’d share some real world experience in this area to see just how real these fears are.

So, how does Janssen-Cilag handle YouTube? First, let’s take a look at their video. [If you're having trouble viewing it, you can view it on YouTube. If you have YouTube blocked by your company, then that's another problem altogether.]

First off, this is a well done video. I like it. This is rule number one of YouTube. If you don’t have quality content, then don’t post it. When I’ve asked some companies about why they block comments, but also ratings, they have responded with something like this: “Well, we’re afraid that people won’t rate our videos very well.” Hmmm, is that a YouTube problem or an indication that your videos aren’t very good? But I digress.

By pretty much any standard on YouTube, Janssen-Cilag’s video has been a success. At the time of this post, there were 71,637 views. Considering this video has been up for a little under a month, that’s pretty impressive. For perspective, that’s more views than all but 5 of the 300 videos on the Johnson and Johnson YouTube channel (my personal favorite pharma YouTube channel) and each of these have been up for more than a year. Like the J&J channel and all its videos, the Janssen-Cilag also allows comments and ratings. At the time of this post, there were 54 published comments. So, is that a lot?

Gary’s take:

“Consider videos on the subject of ADHD – Typically the number of people who leave a comment after viewing varies between 0.05% and 0.5%.  It seems that the barrier to entry of logging in to post a comment is either a bridge too far, or that folk are just happy to be entertained rather than engaged.”

For those not interested in doing the math, Janssen-Cilag’s video has a comment rate of 0.08%. That means there’s one posted comment for every 1,250 views. I agree with Gary that this is a pretty typical number. However, for perspective, the one Johnson and Johnson video about ADHD, has been up for a little more than a year and has 64,726 views, but 322 comments. That’s a rate of 0.5% or one posted comment for every 200 views. The big question is why the difference? Answer: I’m not sure, but stay tuned.

So, is the number of comments lower than what should be expected for the Janssen-Cilag’ video?

Gary’s take:

“I say emphatically no,  the comments are diverse in nature and you can witness dialogue between ideological adversaries.  Its great to see feedback in PR Week and on the YouTube channel itself that suggest at first glance the site appears unmoderated.”

I agree with Gary on this one. There is a free-flowing debate and discussion happening around this video and it certainly isn’t one that you’d expect a pharma company to allow especially if they have the ability to prevent it. It’s a pretty heated debate. In fact, to Gary’s point, one commenter asked, “Are comments even being screened for this video?” Gary promptly responded with: “Yes comments are reviewed before posting – in line with the commenting policy on the site. The vast majority of comments have been posted, Kind regards, Gary.”

Since Gary mentioned the commenting policy, you should read it for yourself by going to the video on YouTube and clicking the double-down arrow immediately to the left of the view total (right under the view itself). The commenting policy is posted and clear [italics added]:

COMMENTING POLICY
All submissions will be reviewed and may not be posted if deemed inappropriate. Comments which are off-topic, offensive, or promotional, will not be posted. Please note that we will not post comments about any specific products or treatments, whether they are sold by Janssen-Cilag Ltd or not.

The comments contained on this site come from members of the public, and do not necessarily reflect the views of Janssen-Cilag, and no endorsement or approval of their content should be implied. Comments that contain links to third-party or commercial Web sites may not be posted; please note that any Web sites that may appear in comments are not endorsed or supported by Janssen-Cilag.

A policy like this is a must if you are going to moderate comments and this one is simple, to the point and also fair. There are some things that aren’t going to be allowed like mentioning specific products because this would require some form of fair balance (or would it?). Based on this commenting policy, how many comments would you expect had to be removed by Janssen-Cilag? Before you answer, recall that anything considered “off-topic, offensive, or promotional” is excluded along with any mention of any product (Janssen-Cilag’s or not). Also, keep in mind that this is a pretty contentious subject with some people arguing that “big pharma” is over-medicating kids, etc. You’ve heard the rumblings, so, you might expect a ton of anti-pharma rhetoric, right?

Gary’s take:

“So far only 7 comments have not been allowed on, in line with the site posting policy.  3 of these mentioned specific medical products and the other 4 were deemed too offensive to post.

Moderating the comments is more straightforward for those that discuss ADHD as a condition or the video, and additional internal discussion is required for comments that allude to treatment, medical advice and strong language.   Clearly the process needs to be robust and compliant yet ideally allow quick postings to site and subsequent engagement.”

Only 7 haven’t been allowed. What did you guess? Most of you probably guessed more. Point is that it’s likely not as bad as what you think. In fact, most discussion and the overall reaction to this particular video has been quite positive. There are 47 likes and only 9 dislikes for this video. That means that 84% of people had a favorable view of the video…a pretty good rate. I’m guessing that most pharma companies would be pretty happy if the public viewed everything else they did at this positive rate.

So, is Gary happy with the results to this point?

Gary’s take:

“My personal opinion is this is a great start, however I see it as a first step and I look forward to a future of increased engagement between pharma, patients and the public:  a future where regulation is seen as an opportunity to do the right thing by patients and not as a barrier to engagement.”

Again, I agree with Gary. His last sentence should be the one you remember: “a future where regulation is seen as an opportunity to do the right thing by patients and not as a barrier to engagement.” Imagine that.

One thing many of you are probably wondering about is how exactly you moderate comments on YouTube. Can it be done? Recall from past posts that you cannot pre-moderate comments or posts on Facebook. That is, you cannot review them before they are posted. As page owner you can remove them after they are posted only. YouTube is different. As the owner of a video (i.e., the person who uploaded it), you are given a number of different options to control. This is the panel you’ll see when you’re saving your video just before making it live.

As you can see, there’s quite a bit you can control. There’s no reason to block all comments (“Don’t allow comments” option) when you can select the option to approve them before posting (“Allow all comments with approval only”). This is similar to how most blogs work, so people are familiar with the process. Note that you can remove them after approving too if necessary.

Comments are critical for the reasons Gary outlined, but also because of YouTube’s search algorithm. I won’t get into too many details here, but the number of comments and ratings play a major role in where your video shows up in the YouTube search results. You probably optimize your websites to ensure they appear on the front page of Google results for as many important keywords as possible (you do, right?), but do you do the same for your YouTube videos? If you’re like most people, you probably aren’t familiar with the fact that there even is an algorithm that determines the order videos appear in YouTube search much less what the algorithm is. Never fear, Dose of Digital has you covered. Just review my post, “8 Tips to Help You Own YouTube’s Search Results” and you’ll be caught up.

So, ready to allow comments and ratings on your YouTube videos yet?

[A couple of housekeeping items on this post. First, from Gary, "Disclaimer: the opinions expressed in this blog are mine and don't necessarily reflect those of my company." Also, Gary will be discussing this project in more detail at Digipharm, in London on September 30th. In the meantime you can always follow him on Twitter: @GaryMonk.]

Why Your Facebook Page Doesn’t Exist

Dose of Digital Mini White Paper

Over the past year or so, many pharma and healthcare companies have jumped into social media with many trying their hand at Facebook. You can see the full list on the Pharma and Healthcare Social Media Wiki. Just click down to the Facebook section. There you’ll see around 50 examples (and I’ll be adding about 5 more in the next update). [Note that this post is applicable to every industry and isn't pharma or healthcare specific.]

Nearly all of these pages have one thing in common. They do not allow comments on the page’s Wall. There are a number of different ways I can argue why this isn’t the best approach, but the rationale often given to me by these companies are related to three things. First, they don’t want people to post adverse events on the page or, second, they don’t want people to post off label information about the product, and, third, they don’t want to deal with negative comments of any sort. In today’s post, I’m not going to argue why these aren’t great excuses. I’ll save that for some other time.

There’s another side effect of not allowing commenting. If you turn off commenting, you also turn off the Like function. You can’t have one without the other. Of course, the Like is far less “dangerous” than a comment, as you can’t add commentary to a Like on the Facebook Wall. You just Like it. That’s it. So, I think most companies would, er, like to allow Fans to be able to Like  individual Wall posts and updates, but they are not willing to allow commenting to make this happen.

The end result is that Wall posts and status updates receive no comments and no Likes. So, what’s the big deal?

First, let’s remember that most of your actions on Facebook will appear on your Wall.

For example:

Next, let’s say that you are the admin for a brand page (like Dose of Digital’s…sorry, couldn’t resist a promotion opportunity). When you do a Wall post or status update, what happens to it?

Here’s a recent one from Dose of Digital’s Facebook Page:

What you probably think happens (if you’re like most people) is that all of the “Fans” of your Page will see this post. But, it’s likely that the vast majority don’t and, in fact, it’s possible that not a single one of them sees it.

Once you Like (previously Fan) a Page, you essentially subscribe to updates from that Page. Of course, you’re not going to visit every Page that you Like each day, so Facebook makes it easy for you by having a feed of all these updates in one place. It’s your News Feed. This is what you see when you first log into Facebook. It looks a little like this:

Familiar, right?

Stay with me because I’m about to show you the problem you have by not allowing comments and Likes.

Many of you probably have never noticed the setting at the top of the Feed…

By default, everyone’s Feed is set to “Top News.” But what exactly is “Top News”? Before I explain that, I’ll explain the simpler option, “Most Recent.” If you click on “Most Recent,” your Feed will change to show, get this, the most recent updates, posts, Likes and comments (etc.) from your friends and the same from pages you have Liked. It’s strictly based on the time the update was made with the most recent at the top. Raise your hand if you thought that your Feed was showing content in this form by default. Those with your hands up, thanks for being honest. That’s what most people think.

“Top News” is a bit trickier and is also the default setting for the feed. In this setting, the Feed is trying to show you the content that it believes is most meaningful or interesting to you out of all the possible content from your friends and Pages you Like. That means that the newest item isn’t at the top, but rather the item with the highest EdgeRank. “The what?”, you say.

EdgeRank is the algorithm that Facebook uses to determine the order of items in your Feed. In the end, it’s really simple, as it has just three factors: affinity, edge, and decay. Fancy words, but here’s what they are. Affinity is basically the connection between you and the piece of content. The more times you’ve interacted with the source of the content (Facebook calls it an “object”) in the past, the higher the affinity. For example, if you comment on your sister’s Wall everyday, content from your sister will have a high affinity score because you interact a lot with her. Second is “edge.” It sounds cooler than it is. All that edge refers to the relative weight of objects. For example, a comment on a Wall Post probably carries more weight than a Like because it take more effort to post a comment. I say probably because this is the proprietary part of the algorithm. Last, and simplest, is decay. This is the time that has past since the object was created.

Multiply the individual scores for each possible object and then arrange the content accordingly. That’s how your News Feed is populated. Now you know. Sleep easy tonight.

Why should you care?

If you’re someone responsible for a brand Facebook Page, you should care quite a lot because EdgeRank is what is likely preventing anyone from ever seeing your content. The reality of the News Feed is that people browse the top entries and dive in when they see something interesting. Sometimes they’ll come right back to the News Feed and many other times, they’ll head somewhere totally unrelated based on something else they find. People certainly don’t read one News Feed item after another until they get to the end. If your content is showing up towards the top of people’s News Feed, you create a virtuous cycle. If more people see it, then more people comment and Like it. The more people that do this, the more their Likes and comments related to your content show up on their Walls, and therefore, their friends’ News Feeds. This exposes your content to more potential Fans who then Like your page and leave comments. This ensures that your content is even higher on  more News Feeds and so on. For example, I’m a Fan of Mashable on Facebook. Everytime they put out something new it’s right around the top 2 or 3 stories in my News Feed. It’s because I interact  with (read, comment, Like, etc.) many of these posts and so do hundreds of others.

So, the question is this: Does your content ever show up among the first few items on anyone’s News Feed?

To answer this, let’s bring back EdgeRank. First, affinity. If you’re like most pharma and healthcare brands, your affinity score is pretty low. Because you don’t allow commenting or Likes, people don’t interact with you very often. Maybe they read an Update (assuming they see it), but that’s it. Because you probably don’t do regular updates, they probably don’t even do this very often. Low affinity…check. Next is edge. Interactions that require a bit of effort rank higher than those that don’t. From my earlier example, leaving a comment takes more effort than simply Liking something. Similarly, posting a photo requires more work than a text update. You get the idea. Because the only thing you’re likely doing with your page is Wall posts (that are likely just text), there isn’t much edge. These are low engagement activities that score the lowest. People have to interact with your content to create more edge. Finally, we come to decay. If you aren’t updating regularly, then your Posts will always suffer from a low score here as well. The only way to improve decay is to make sure you have regularly updated content to increase the number of times that your EdgeRank is calculated for something new, which would have a higher decay score.

For those scoring at home, most pages will be zero for three. The consequence of this is that all the effort you put into building your Fans on Facebook might have been a complete waste. The point of having Fans is that you can communicate with them. The best way to do this is for them to see your new content. The place they see new content is in their News Feed. But your content probably isn’t in their News Feed. As far as your Fans are concerned, your page may as well have been deleted.

So, now that I’ve got your attention, how do you know if anyone is seeing your content? Facebook recently upgraded their analytics to let you see both the number and types of interactions with content (comments, Likes, etc.) and also the number of impressions. Facebook’s definition of an “impression” is anytime it serves (displays) a certain piece of content. It doesn’t mean that someone actually read it, but that it was there. The content could have been served in a number of places including user’s news feed, a visit to the Page, or through an Open Graph social plugin (which include many of the ones seen here). This is similar to how impressions for banner ads on websites are measured. That is, impressions are the number of visitors who could have seen the banner, not the number that actually saw it.

How do you find the number of impressions for your content? When you are logged into an account that is an admin for the Page you’re interested in, go to: http://www.facebook.com/insights. You’ll get to a page like this:

A word of caution here…many people have reported bugs with the data from these insights pages that cause inaccurate or missing data. It’s the best we have though, so stay with me. This is what the insights page looks like for a given Facebook Page:

I can tell you that for my Page, the interactions numbers are wrong, but let’s continue. If you click on the “See Details” link next to Interactions, you end up here:

What’s missing here and what we need to figure out the number of impressions is, well, the number of impressions. You see that for me, “n/a” is all that appears. There are two different explanations for this, which I’m working on figuring out which is true (or if both are). I’ll post an update to this post when I get an answer from Facebook. Explanation 1: Impressions are only available for Pages with more than 5,000 Fans. This was given by Facebook as the cutoff when they first announced that per post impression data would be available earlier this year. If this is the case, then most pharma and healthcare pages aren’t going to get impressions data. Explanation 2 (potentially related to explanation 1): Facebook answers an FAQ about this noting that “Per-post insights are only available on verified, authentic Pages. If your Page is not verified as authentic, then this feature is not available.” No mention of 5,000 Fans here. So, if you have less than this, then you might be golden. Unfortunately, Facebook doesn’t tell you how to verify your page in their answer. But, one of the reasons you read this blog is because you know I have to figure this stuff out. So, here’s a link to the form you need to fill out to get your Page verified (hat tip to Inside Facebook for this one). How long that takes or if it works is anyone’s guess.

If you can see insights information right now, then great. Is is what you expected? Higher or lower? On average, it’s a 1:1 ratio for impressions to Fans. That is, if you have 1,000 fans, your Wall Post, for example, will typically get 1,000 impressions. This isn’t because every Fan actually was served the content (much less saw it), but because some were served it multiple times. Remember, impressions don’t mean that people actually saw and read the content much less engaged with it. However, this ratio only holds true for brands that post quality content and that have some engagement from Fans. Remember, EdgeRank and how the News Feed works? You’ll get more impressions if your content is always at the top of people’s Feeds. You’ll get way less if it never shows up. The feed displays around 20 of the top pieces of content. If yours is the 21st based on EdgeRank then you won’t even get an impression. To get to the top, you need a high EdgeRank and we’ve already talked about that.

The big point here is simple. By not allowing comments and, therefore, Likes and by updating content rarely and making it mostly text, you’re all but ensuring that your Facebook efforts are reaching no one. Allow comments and with them, Likes. You may have to remove a comment here and there, but that’s okay. You can remove it as soon as it’s posted if you’d like. No harm done. To me, there isn’t a real regulatory risk if you act in good faith. If someone publishes something off-label, for example, to your Wall or as a comment to your post and you remove it at the first chance you get, do you really think that the FDA is going to penalize you for that? You can’t control what people put on the site, you don’t encourage or condone this type of information, and you act on it as soon as you know there’s an issue. I don’t get what the concern is. There are a handful of pharma and healthcare pages out there that have opened up commenting and the vast majority are handling it just fine. In fact, they’re getting people to actively engage with the brand for the first time. Rather than create a nightmare for the brand, it’s a dream come true. Imagine that.

So, does your Facebook page even exist?

7 Links to Read from Dose of Digital

Last week, one of my favorite blogs, Problogger, issued a challenge which I thought was pretty interesting, so that’s what today’s post is all about. [By the way, if you write a blog or are thinking about writing one, be sure to subscribe to Problogger.]

The challenge was pretty simple. Write about 7 past posts that fit into 7 different categories. I didn’t like the idea at first until I went through the 7 categories and saw that it looked like fun. I also think that you’ll find it this post useful if you’re new to this blog. If you’ve Dose of Digital it since the beginning, there’s probably a thing or two that you can use to refresh your memory or get you thinking a bit differently on a Monday. Here are the 7 categories:

  • Your first post
  • A post you enjoyed writing the most
  • A post which had a great discussion
  • A post on someone else’s blog that you wish you’d written
  • Your most helpful post
  • A post with a title that you are proud of
  • A post that you wish more people had read

Your first post: This one wasn’t too inspired, but a mere welcome to Dose of Digital, which was aptly titled:”Welcome Readers to Dose of Digital.” I didn’t intend to write much about social media when I started the blog back in December 2008, but that’s turned out to be the hot topic in the industry over the past year or so. However, I guess I did have a little foresight when I explained one of the things I hoped to accomplish with the blog: “Can something like Facebook or YouTube really save lives by improving healthcare? The answer is yes and I hope to show you how.” It’s still a work in progress.

A post you enjoyed writing the most: This was the easiest of the categories to come up with. It was my post “14 Things That Will Inspire Your Digital Marketing in 2010.” I wrote this on January 4, 2010 to be something to help you start the year out right. If you haven’t seen it yet and need a little inspiration, be sure to check it out.

A post which had a great discussion: My post “Pharma Should Forget About Social Media Monitoring” not only had the best discussion, but also probably the most in-depth (most comments) and deepest discussion. Read the comments for sure on this one, as some people put together responses that were worthy of their own blog posts. I think the controversial sounding title was one of the biggest reasons for the intense debate.

A post on someone else’s blog that you wish you’d written: This was the hardest of all the categories to come up with, as I read so many great posts everyday that I look at and say, “Wow, that perfectly says what I was trying to explain,” or “Hmm…I never thought of it that way, but it’s perfectly clear now.” One post like that was “5 ways to ignite a social media frenzy” that was written by Brandon Evans, CEO of Crowdtap. I’ve used a couple of examples from Brandon’s article in some of my presentations and should probably give him more credit than I have, so here it is. If you want to know why some social media programs work and others don’t, this is a great place to start.

Your most helpful post: The post for this category is actually a very recent one: “The Beginner’s Guide to Pharma Social Media.” I answer a lot of questions about social media in healthcare and pharma everyday, so this post is one that let’s you catch up on all of it in one place. If you’re new to the space or really want to refresh your thinking, be sure to check it out. If you read every link in the post and review every presentation and paper, it’ll take you a solid 8 hours to review, so feel free to pick and choose what looks good to you.

A post with a title that you are proud of: This was a tough one, as I’m particularly proud of a lot of titles (if not the posts) because I pride myself on coming up with catchy ones. I’d say about 20% of the time, they’re actually as good as I think they are. Oh well. One that I love (and also loved writing the post) is: “10 Healthcare Dinosaurs Digital Technology Will Make Extinct.” This also includes a picture of a dinosaur (the bones at least), so I think this makes the whole thing score higher.

A post that you wish more people had read: I’m going to cheat a little on this one and give you two, but I think I’m okay because the posts are really a series. They are “7 Biggest Mistakes in Digital Relationship Marketing” and “The 7 Golden Rules in Digital Relationship Marketing.” I think these posts are pretty helpful for anyone involved in digital marketing regardless of the industry. I also think that healthcare and pharma companies have a long way to go with their relationship marketing efforts, so it should be required reading for some of these folks. As a bonus, you can get the two posts in one neat PDF here: The Biggest Mistakes and Golden Rules of Digital Relationship Marketing (990 downloads)

So that’s the 7 categories. I hope you found something useful you haven’t seen before or that was a good refresher. If you write a blog, I’ll issue you the challenge to come up with a similar “7 links” post. If you do, be sure to post a link to it in the comments.

An Award for Dose of Digital…Thanks

If you’re looking for a ton of social media insight or for the latest trends in digital technology in healthcare, today’s post isn’t going to cover much of that. If you want some of the former, then definitely check out “The Beginner’s Guide to Pharma Social Media.” For a bit of the latter, well, you’ll can check out pretty much everything else.

Today’s post has two purposes: first, to announce a major award that Dose of Digital just received, and second, to say thank you for your support in making this award possible.

As many of you know, I work for Bridge Worldwide, which is part of one of the largest agency holding companies, WPP. Each year, WPP has an internal contest called the Atticus Awards. In their words, “WPP’s Atticus Awards honour original thinking in communications services and are open exclusively to professionals working in WPP companies. Each year, extracts from the winning and other outstanding entries are published in the Atticus Journal.” You can follow the link and see some of the past winners, which last year included the outstanding books, The Brand Bubble by John Gerzema, and Personality Not Included by Rohit Bhargava (full list of last year’s winners here in PDF). Awards come in three levels for eight different categories: “Winner,” “Highly Commended,” and “Merit.” There’s also a “Grand Prix,” which is basically a best in show.

I’m pleased to announce that Dose of Digital was just selected as “Highly Commended” in the Digital Communications category in this year’s Atticus Awards. It’s a pretty big honor considering the competition and the past winners, which consist of some of the best and brightest out there. (Check out last year’s “Highly Commendable” winner in the Digital Communications category from Ann Mack at JWT called, “Privacy in the Digital Age [PDF].” Pretty timely.)

As part of this honor, I’d like to thank each of you for your continued readership and support. Without the encouragement I get from you (and the ideas), I likely would have given up on the blog a long time ago. Please let me know if there’s anything you want me to cover on the blog that you haven’t seen yet. It’s the least I can do. As regular readers know, I’m happy to give my opinion on whatever the topic no matter how much controversy I’m likely to stir up.

I also want to take a minute and congratulate by colleague, Bob Gilbreath, for being named a “Merit” winner for his outstanding book, Marketing With Meaning, in the Strategy category (feel free to congratulate him via Twitter at @mktgwithmeaning). If you ask me, that book was more than “Winner” worthy, but it must have been tough competition, as the eventual “Grand Prix” winner also came from the Strategy category. It’s pretty exciting to have two awards for our agency in a single year. If you haven’t read Bob’s book, get it. Get it especially if you work in pharma or healthcare. To me, the concept of Marketing with Meaning applies more here than to any other industry. If you want to see how, check out my series of posts on the topic starting with this one: “How Marketing with Meaning Can Save Pharma — Part 1.”

[Side note: the full list of winners for this year's Atticus Awards hasn't been fully released yet. I'll let you know when they are and where you can get a copy of the journal with excerpts from all the Winners and several other top entries.]

Again, thanks for your support and continued inspiration. Look out for more controversy coming soon…gotta make a run at that “Grand Prix” award next year.

Older Posts »